research A Case of Unexpected Successful Treatment of Alopecia Areata With Tralokinumab in a Patient With Atopic Dermatitis
Tralokinumab successfully treated alopecia areata in a patient with atopic dermatitis.
Search
for
Sort by
Research
300-330 / 1000+ results research Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme
Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.
research Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
research Treating Psoriasis: What Is New About Fumaric Acid Esters?
Fumaric acid esters, especially dimethylfumarate, improve psoriasis treatment.
research Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and Contact Immunotherapy in the Treatment of severe alopecia areata: a systematic review and network meta-analysis
Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
research FORMULATION AND EVALUATION OF TRIAMCINOLONE ACETONIDE SERUM WITH DERMA STAMP ASSISTED DELIVERY FOR THE MANAGEMENT OF ALOPECIA AREATA
The serum with microneedling effectively treats alopecia areata by enhancing drug delivery and is safe and patient-friendly.
research Tofacitinib in alopecia areata and HIV: A curious intersection of immunomodulation, hair regrowth, and hypertrichosis
Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.
research Case Series and Literature Review on Tofacitinib for Treating Severe Alopecia Areata
Tofacitinib is effective and safe for treating severe alopecia areata.
research Real‐World Efficacy and Safety of Tofacitinib for Patients With Alopecia Areata: A Retrospective Multi‐Center Cohort Study
Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.
research Increased risk of telogen effluvium with tirzepatide compared to other weight-loss medications: a retrospective cohort TriNetX database study
research Exploring the historical stigma of spironolactone use in breast cancer survivors with alopecia
Spironolactone is safe for breast cancer survivors with alopecia and does not increase cancer risk.
research Lokaltherapie der Alopecia androgenetica mit 17α-Östradiol
17α-estradiol lotion can reduce hair loss but doesn't promote new hair growth.
research Enhanced Skin Permeation and Controlled Release of β-Sitosterol Using Cubosomes Encrusted with Dissolving Microneedles for the Management of Alopecia
The new delivery system improved hair growth in alopecia treatment.
research Striae distensae over scalp: a trichoscopic revelation
Trichoscopy can detect early signs of steroid overuse on the scalp, suggesting a need for non-steroidal treatments.
research Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial
Setipiprant did not significantly improve hair growth in men with hair loss.
research Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO ‐LT phase 3, open‐label study
Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
research Psoriasis in the limelight: the remarkable career of an old skin disease
Tofacitinib may be an effective and safe treatment for adolescent alopecia areata.
research FASCE, the benefit of spironolactone for treating acne in adult females: study protocol for a randomized double-blind trial
Spironolactone is a promising alternative to antibiotics for treating acne in adult females.
research Correction to ‘Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study’
research Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
research Sequential Immunotherapy with Tofacitinib and Low-Dose IL-2 Induces Sustained Remission in Alopecia Areata: A Proof-of-concept monocentric study
Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.
research The anxiolytic-like effects of estazolam on a PTSD animal model
Estazolam reduces anxiety-like behavior in PTSD by increasing allopregnanolone levels.
research Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne
Spironolactone is better than placebo for reducing excessive hair growth in women, but its effectiveness for acne is unclear due to small study sizes.
research PC-SPES Studies Promising, But Manufacturer Shuts Down
Promising cancer treatments were found, but the manufacturer closed.
research 598 Response to ritlecitinib treatment based on salt improvement scores in patients with alopecia areata (AA): Post hoc analysis of the allegro phase 2b/3 study
Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
research Treatment of chronic alopecia areata with tildrakizumab: an open‐label pilot study
Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
research Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
research Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
research Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.
research Granulation Tissue that Developed after a Minor Trauma in a Psoriatic Patient on Long-term Etretinate Therapy
Long-term etretinate use may cause delayed wound healing and extra tissue growth after injury.